Departments of Epidemiology and Biostatistics, Division of General Internal Medicine/San Francisco General Hospital, University of California, San Francisco, CA, USA.
Pain Med. 2012 Sep;13(9):1174-80. doi: 10.1111/j.1526-4637.2012.01430.x. Epub 2012 Jul 3.
Pain medicine agreements are frequently recommended for use with high-risk patients on chronic opioid therapy. We assessed how consistently pain medicine agreements were used and whether patients were aware that they had signed a pain medicine agreement in a sample of HIV-infected adults prescribed chronic opioid treatment.
We recruited patients from a longitudinal cohort of community-based HIV-infected adults and recruited the patients' primary care providers (PCPs). The patients completed in-person interviews and PCPs completed mail-based questionnaires about the patients' use of pain medicine agreements. Among patients prescribed chronic opioid therapy, we analyzed the prevalence of pain medicine agreement use, patient factors associated with their use, and agreement between patient and clinician reports of pain agreements.
We had 84 patient-clinician dyads, representing 38 PCPs. A total of 72.8% of patients fit the diagnostic criteria for a lifetime substance use disorder. PCPs reported using pain medicine agreements with 42.9% of patients. Patients with pain medicine agreements were more likely to be smokers (91.7% vs 58.3%; P = 0.001) and had higher mean scores on the Screener and Opioid Assessment for Patients with Pain (µ = 26.0 [standard deviation, SD] = 9.7) vs µ = 19.5 [SD = 9.3]; P = 0.003). Patients reported having a pain medicine agreement with a sensitivity of 61.1% and a specificity of 64.6%.
In a high-risk sample, clinicians were using agreements at a low rate, but were more likely to use them with patients at highest risk of misuse. Patients exhibited low awareness of whether they signed a pain medicine agreement.
疼痛药物协议常被推荐用于接受慢性阿片类药物治疗的高风险患者。我们评估了在接受慢性阿片类药物治疗的 HIV 感染成人样本中,疼痛药物协议的使用是否一致,以及患者是否意识到他们签署了疼痛药物协议。
我们从一个基于社区的 HIV 感染成人纵向队列中招募患者,并招募了患者的初级保健提供者(PCP)。患者完成了面对面访谈,PCP 完成了基于邮件的问卷,内容涉及患者使用疼痛药物协议的情况。在接受慢性阿片类药物治疗的患者中,我们分析了疼痛药物协议使用的流行率、与使用相关的患者因素,以及患者和临床医生对疼痛协议报告的一致性。
我们有 84 对患者-临床医生,代表 38 名 PCP。共有 72.8%的患者符合终生物质使用障碍的诊断标准。PCP 报告有 42.9%的患者使用疼痛药物协议。使用疼痛药物协议的患者更有可能吸烟(91.7% vs 58.3%;P = 0.001),且疼痛评估筛查和患者疼痛评估(µ = 26.0 [标准差,SD] = 9.7)的平均得分更高 vs µ = 19.5 [SD = 9.3];P = 0.003)。患者报告有疼痛药物协议的敏感度为 61.1%,特异性为 64.6%。
在高危人群中,临床医生使用协议的比例较低,但更有可能与最有可能滥用的患者一起使用协议。患者对是否签署了疼痛药物协议的意识较低。